373 related articles for article (PubMed ID: 28581273)
21. Guillain-Barré syndrome after vaccination in United States: data from the Centers for Disease Control and Prevention/Food and Drug Administration Vaccine Adverse Event Reporting System (1990-2005).
Souayah N; Nasar A; Suri MF; Qureshi AI
J Clin Neuromuscul Dis; 2009 Sep; 11(1):1-6. PubMed ID: 19730016
[TBL] [Abstract][Full Text] [Related]
22. Vaccines and the risk of Guillain-Barré syndrome.
Chen Y; Zhang J; Chu X; Xu Y; Ma F
Eur J Epidemiol; 2020 Apr; 35(4):363-370. PubMed ID: 31858323
[TBL] [Abstract][Full Text] [Related]
23. [Clinical features of children with Guillain-Barré syndrome and the significance of Brighton criteria].
Liang JF; Sun RD; Wang RX; Luo J; Wang HD; Jiang J
Zhongguo Dang Dai Er Ke Za Zhi; 2021 Feb; 23(2):153-157. PubMed ID: 33627210
[TBL] [Abstract][Full Text] [Related]
24. Signals and trends of Guillain-Barré syndrome after the introduction of live-attenuated vaccines for influenza in the US and South Korean adverse event reporting systems.
Lee H; Kim HJ; Choe YJ; Shin JY
Vaccine; 2020 Jul; 38(34):5464-5473. PubMed ID: 32600907
[TBL] [Abstract][Full Text] [Related]
25. Recurrent Guillain-Barre syndrome following vaccination.
Baxter R; Lewis N; Bakshi N; Vellozzi C; Klein NP;
Clin Infect Dis; 2012 Mar; 54(6):800-4. PubMed ID: 22267712
[TBL] [Abstract][Full Text] [Related]
26. Clinical features of patients with Guillain-Barré syndrome at seven hospitals on the East Coast of Australia.
Blum S; Reddel S; Spies J; McCombe P
J Peripher Nerv Syst; 2013 Dec; 18(4):316-20. PubMed ID: 24172315
[TBL] [Abstract][Full Text] [Related]
27. Guillain-Barré syndrome following influenza vaccination.
Haber P; DeStefano F; Angulo FJ; Iskander J; Shadomy SV; Weintraub E; Chen RT
JAMA; 2004 Nov; 292(20):2478-81. PubMed ID: 15562126
[TBL] [Abstract][Full Text] [Related]
28. Serious adverse events following receipt of trivalent inactivated influenza vaccine in Korea, 2003-2010.
Choe YJ; Cho H; Kim SN; Bae GR; Lee JK
Vaccine; 2011 Oct; 29(44):7727-32. PubMed ID: 21827815
[TBL] [Abstract][Full Text] [Related]
29. Incidence and outcome of Guillain-Barré syndrome in Iceland: A population-based study.
Hafsteinsdóttir B; Ólafsson E; Jakobsson F
Acta Neurol Scand; 2018 Nov; 138(5):454-458. PubMed ID: 30019469
[TBL] [Abstract][Full Text] [Related]
30. Guillain-Barre syndrome, influenza, and influenza vaccination: the epidemiologic evidence.
Vellozzi C; Iqbal S; Broder K
Clin Infect Dis; 2014 Apr; 58(8):1149-55. PubMed ID: 24415636
[TBL] [Abstract][Full Text] [Related]
31. Guillain-Barré syndrome subtypes: A clinical electrophysiological study of 100 patients.
Grapperon AM; Berro M; Salort-Campana E; Verschueren A; Delmont E; Attarian S
Rev Neurol (Paris); 2019; 175(1-2):73-80. PubMed ID: 30442448
[TBL] [Abstract][Full Text] [Related]
32. Locked-in syndrome in three children with Guillain-Barré syndrome.
Medici C; Gonzalez G; Cerisola A; Scavone C
Pediatr Neurol; 2011 Aug; 45(2):125-8. PubMed ID: 21763955
[TBL] [Abstract][Full Text] [Related]
33. Guillain-Barré syndrome: background incidence rates in The Netherlands.
van der Maas NA; Kramer MA; Jacobs BC; van Soest EM; Dieleman JP; Kemmeren JM; de Melker HE; Sturkenboom MC
J Peripher Nerv Syst; 2011 Sep; 16(3):243-9. PubMed ID: 22003939
[TBL] [Abstract][Full Text] [Related]
34. Bickerstaff Brainstem Encephalitis and overlapping Guillain-Barré syndrome in children: Report of two cases and review of the literature.
Michev A; Musso P; Foiadelli T; Trabatti C; Lozza A; Franciotta D; Simoncelli AM; Savasta S
Eur J Paediatr Neurol; 2019 Jan; 23(1):43-52. PubMed ID: 30502045
[TBL] [Abstract][Full Text] [Related]
35. Risk of Guillain-Barré syndrome after exposure to pandemic influenza A(H1N1)pdm09 vaccination or infection: a Norwegian population-based cohort study.
Ghaderi S; Gunnes N; Bakken IJ; Magnus P; Trogstad L; Håberg SE
Eur J Epidemiol; 2016 Jan; 31(1):67-72. PubMed ID: 26008750
[TBL] [Abstract][Full Text] [Related]
36. Outcome of axonal and demyelinating forms of Guillain-Barré syndrome in children.
Tekgul H; Serdaroglu G; Tutuncuoglu S
Pediatr Neurol; 2003 Apr; 28(4):295-9. PubMed ID: 12849884
[TBL] [Abstract][Full Text] [Related]
37. Cerebrospinal fluid findings in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathies.
Illes Z; Blaabjerg M
Handb Clin Neurol; 2017; 146():125-138. PubMed ID: 29110767
[TBL] [Abstract][Full Text] [Related]
38. [Analysis of differences in epidemiology and clinical features of Guillain-Barré syndrome between rural and urban areas of southern China].
Zhou RM; Shao B; Luo C; Dai HY; Xu J; Li XY; Wang N; Zhang RX; Ji F; Yang B; Jiang ZW; Hu F; Liu SP; Yao JJ; Liu Y; Zhou YW; Guan JX; Xiao ZM; Lu ZN
Zhonghua Yi Xue Za Zhi; 2019 Nov; 99(43):3432-3436. PubMed ID: 31752474
[No Abstract] [Full Text] [Related]
39. Guillain-Barré syndrome in association with COVID-19 vaccination: a systematic review.
Abolmaali M; Rezania F; Behnagh AK; Hamidabad NM; Gorji A; Mirzaasgari Z
Immunol Res; 2022 Dec; 70(6):752-764. PubMed ID: 36098903
[TBL] [Abstract][Full Text] [Related]
40. Clinical characteristics and outcomes of patients with Guillain-Barré and acquired CNS demyelinating overlap syndrome: a cohort study based on a literature review.
Mao Z; Hu X
Neurol Res; 2014 Dec; 36(12):1106-13. PubMed ID: 24914906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
